Home

AbbVie (ABBV)

191.50
+2.00 (1.06%)
NYSE · Last Trade: Jun 11th, 5:25 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close189.50
Open189.34
Bid191.00
Ask191.50
Day's Range189.06 - 192.72
52 Week Range163.52 - 218.66
Volume3,907,201
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.560 (3.43%)
1 Month Average Volume6,348,492

Chart

About AbbVie (ABBV)

AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More

News & Press Releases

How Is The Market Feeling About AbbVie?benzinga.com
Via Benzinga · June 11, 2025
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infectionbenzinga.com
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
Via Benzinga · June 11, 2025
Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stockbenzinga.com
Via Benzinga · June 10, 2025
1 S&P 500 Stock with Competitive Advantages and 2 to Steer Clear Of
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · June 9, 2025
3 Stocks With Mouthwatering Dividends You Can Buy Right Nowfool.com
Via The Motley Fool · June 8, 2025
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocksfool.com
Via The Motley Fool · June 5, 2025
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Pointbenzinga.com
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 4, 2025
3 Cheap Dividend Growth Stocks to Buy Right Nowfool.com
Via The Motley Fool · June 4, 2025
4 Forever Dividend Stocks to Buyfool.com
These companies provide growing cash flows.
Via The Motley Fool · June 3, 2025
Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'benzinga.com
Via Benzinga · June 2, 2025
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lillyinvestors.com
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 28, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 27, 2025
AbbVie To Present Cancer Trial Data At Upcoming ASCO Eventbenzinga.com
AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.
Via Benzinga · May 27, 2025
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Resultfool.com
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
Via The Motley Fool · May 24, 2025
Elon Musk Commits to Tesla. Is That a Good Thing?fool.com
Via The Motley Fool · May 23, 2025
2 Incredible Dividend Growth Stocks to Buy Nowfool.com
Via The Motley Fool · May 21, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 20, 2025
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.fool.com
Here are three dividend-paying stocks that warrant closer examination.
Via The Motley Fool · May 18, 2025
3 Magnificent Stocks That Are Passive Income Machinesfool.com
Via The Motley Fool · May 17, 2025
3 Stocks That Will Profit From Trump's Drug Price Cutbenzinga.com
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Via Benzinga · May 16, 2025
1 Healthcare Stock to Keep an Eye On and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.
Via StockStory · May 16, 2025
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025benzinga.com
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Betsbenzinga.com
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Via Benzinga · May 15, 2025